相关临床试验
400
47 进行中
药物批准
19
批准总数
监管机构
3
监管机构数
成立时间
N/A
进行中（未招募）
44
11.0%
Approved For Marketing
3
0.8%
Available
2
0.5%
已完成
298
74.5%
No Longer Available
2
0.5%
尚未招募
3
0.8%
招募中
3
0.8%
暂停
1
0.3%
终止
35
8.8%
Unknown
1
0.3%
撤回
8
2.0%
- A first-in-class PET radiotracer, 18F-OXD-2314, demonstrated elevated uptake in grey-white matter junctions of retired athletes with suspected CTE compared to healthy controls. - The tracer also showed binding in all post-mortem CTE tissue examined, providing early biological confirmation of its ability to detect tau pathology specific to CTE. - Separately, the Alzheimer's-associated protein eMTBR-tau243 showed stage-specific increases in blood samples from donors with confirmed CTE pathology, rising from Stage I to Stage IV disease. - Both approaches could provide the first accurate in-life diagnostic biomarkers for CTE, potentially enabling clinical trials and offering patients clarity within the next two years.
- Researchers at St. Jude Children's Research Hospital have developed a breakthrough combination therapy using indisulam, a molecular glue drug, with anti-GD2 immunotherapy that achieved complete tumor eradication in preclinical neuroblastoma models. - The study, published in Nature Communications, reveals that neuroblastoma cells exhibit more complex plasticity than previously understood, with multidirectional state transitions that enable resistance to single-targeted therapies. - The combination approach exploits indisulam's dual mechanism of disrupting RNA splicing through RBM39 degradation while simultaneously activating natural killer cells and enhancing GD2 expression for improved immunotherapy effectiveness. - This therapeutic strategy addresses a critical unmet need in high-risk neuroblastoma, where nearly half of patients face aggressive treatments with substantial toxicity and relapse rates approaching 50%.
- Aurobindo Pharma Limited has received FDA approval for multiple generic drug formulations, including critical medications for cardiovascular, neurological, and gastrointestinal conditions. - The company's recent approvals include AB-rated generic equivalents to major brand-name drugs such as Eliquis, Pradaxa, Chantix, and Nexium, expanding access to affordable treatment options. - These FDA approvals represent significant additions to Aurobindo's generic drug portfolio, covering therapeutic areas from anticoagulation to smoking cessation and acid reflux management.
- The Phase III LEAP-001 trial evaluated lenvatinib plus pembrolizumab versus chemotherapy as a first-line treatment for advanced or recurrent endometrial cancer. - In patients with mismatch repair-proficient (pMMR) endometrial cancer, the combination therapy did not significantly improve progression-free or overall survival compared to chemotherapy. - The combination therapy showed a slightly longer median progression-free and overall survival in the total population, but the difference was not statistically significant. - The lenvatinib/pembrolizumab arm had a higher incidence of grade ≥3 treatment-related adverse events and treatment discontinuations due to adverse events compared to chemotherapy.
- A phase II study (OLIE) found that adding lenvatinib to ifosfamide/etoposide did not significantly improve progression-free survival (PFS) in pediatric and young adult patients with relapsed osteosarcoma. - Median PFS was 6.5 months in the lenvatinib arm versus 5.5 months in the control arm (HR = 0.54, one-sided P = .04), failing to meet the prespecified significance threshold. - Overall survival was 11.9 months in the lenvatinib group and 17.4 months in the control group (HR = 1.28, one-sided nominal P = .75). - The combination therapy was associated with a higher incidence of grade ≥ 3 treatment-related adverse events (89.7% vs 79.5%) and treatment-related serious adverse events (59.0% vs 30.8%).
